Kimberly‑Clark Completes Acquisition of Kenvue, Settles $7 B Note Exchange

Kimberly‑Clark (ticker: KMB) has officially completed its acquisition of Kenvue, following the settlement of its related $7 billion note exchange program, marking a significant milestone for the S&P 500 consumer‑goods company.

On November 2, 2026, Kimberly‑Clark announced it had completed the acquisition of Kenvue, uniting ten billion‑dollar consumer health brands—including well‑known names like Tylenol, Neutrogena, and Band‑Aid—under its operating umbrella. The deal also leverages Kimberly‑Clark’s so‑called “Powering Care” growth engine to drive integration and value creation. The company reaffirmed anticipated run‑rate synergies of approximately $2.1 billion, comprised of $1.9 billion in cost savings over the first three years and $500 million in revenue synergies within four years, partially offset by about $300 million in reinvestment. The acquisition closely follows the October close of a $4.9 billion senior notes offering arranged to fund the transaction.

Simultaneously, on November 3, KMB finalized the previously announced exchange and consent solicitation for Kenvue’s outstanding notes. Holders who tendered their notes were exchanged for new Kimberly‑Clark notes and a premium, with the settlement scheduled for November 4. This exchange clears the debt ties between Kenvue and Kimberly‑Clark and aligns the capital structure under the acquiring company.

This combination positions Kimberly‑Clark as a leading global health and wellness company with greater scale and diversification across personal care and consumer health categories. It also reinforces its financial framework with expected multi‑year synergy realization and consolidated debt management.

Investors should now watch how integration progresses, especially for synergies capture, margin performance, and any commentary included in the upcoming third‑quarter earnings release scheduled for November 5. These developments will be critical for assessing the long‑term impact of the acquisition on Kimberly‑Clark’s growth trajectory and shareholder returns.